#1 Chicago limits opioid prescriptions for city employees, encourages large employers to do the same
Mayor Rahm Emmanuel announced a seven-day limit for opioid prescriptions for city employees. Click here to read the full press release.
#2 CDC study finds number of women at labor and delivery with opioid use disorder quadrupled
A CDC study reported on August 9, 2018 finds opioid use disorder quadrupled among women at labor at delivery between 1994-2014. Click here to read the press release.
The statement contained the following CDC-recommended actions to prevent opioid use disorder in pregnant women:
- Ensuring appropriate opioid prescribing, in line with the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain.
- Maximizing and enhancing prescription drug monitoring programs, state-based databases that collect, monitor, and analyze controlled substance dispensing.
- Implementing universal substance use screening at the first prenatal visit, as recommended by the American College of Obstetricians and Gynecologists.
- Ensuring pregnant women with OUD have access to medication assisted therapy and related addiction services.
- Ensuring mothers with OUD receive adequate patient-centered postpartum care, including mental health and substance use treatment, relapse-prevention programs, and family planning services.
#3 Persistent opioid use after wisdom tooth extraction
Link between long-term use in teens and young adults and opioid prescriptions related to wisdom tooth extraction surgery shown in JAMA research letter.
Click here to access the JAMA study:
#4 FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder
“The evidence is clear: medication-assisted treatment works, and it is a key piece of defeating the drug crisis facing our country. The FDA’s new guidances have the potential to bring new medications to market that are more closely tailored to patient needs and help give Americans facing addiction a better chance at recovery,” stated HHS Secretary Alex Azar in a press release on Monday August 6, 2018.
Click here to read the full press release.
“As we seek to help those with an opioid use disorder transition to lives of sobriety, we recognize there’s great interest in new treatment options that result in meaningful outcomes for patients. For example, we must consider new ways to gauge success beyond simply whether a patient in recovery has stopped using opioids, such as reducing relapse overdoses and infectious disease transmission. Treatments that can impact these aspects of addiction can be important parts of a comprehensive approach to the treatment of opioid use disorder. This new guidance is an important step in fostering the development of new treatment options that help patients achieve these and other real-world outcomes, by providing a pathway for how innovators can use these clinically relevant measures as part of new drug development programs,” commented FDA Commissioner Scott Gottlieb, M.D. in the same release.
Access the draft guidance document that identifies several additional potential clinical endpoints and other outcome measures that drug developers may consider here: Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment, Guidance for Industry
#5 First and only FDA-approved, non-opioid medication indicated for mitigation of opioid withdrawal symptoms is now available for prescription
LUCEMYRA savings program offered for eligible patients. Click here to read the press release.